Antithromboembolic strategies in XXXX : A review.

@entity1 @entity1187 @entity64 @entity548 @entity2067 @entity303 @entity955 @entity453 @entity3075 @entity715
UNASSIGNED: Oral anticoagulation is highly effective for @entity64 prevention in high-risk- @entity1 with @entity955 . AF is also a risk for @entity303 , and effective OAC reduces the risk of @entity303 . Up to 30% of @entity1 with @entity955 have a @entity453 and antiplatelets are used to avoid @entity715 complications]. @entity1 with @entity955 oft have an @entity1187 und undergo a percutaneous intervention with stent-implantation. These @entity1 require a triple therapy, i.e. the combination of oral anticoagulation with dual-anti-platelet therapy. It is obvious that OAC may induce @entity548 with potentially deleterious effects on mortality. Even the occurrence of minor @entity548 is problematic. The review describes available data on used antithromboembolic regimens in @entity1 treated with oral anticoagulation ( @entity2067 antagonists and non- @entity2067 antagonists) who need a triple therapy (i.e. anticoagulation and antiplatelets). Most data are from @entity1 who were treated for an @entity1187 and cannot be directly extrapolated for @entity1 with @entity955 . The impact of used stents and novel @entity3075 antagonist-antiplatelets and duration of triple therapy is discussed. Often some high-risk @entity1 with @entity955 would need anticoagulation but cannot be given this therapy because of excessive @entity548 risks or contraindicating comorbidities: in these @entity1 left atrial appendage closure with an occluding device can be used as an alternative to antithromboembolic therapy- The unavoidable antithromboembolic triple therapy carries a strong potential for @entity548 events, which increase mortality. We have many data and several recommendations are offered. . Nonetheless, we lack solid data on the best antithromboembolic regimen in @entity1 with @entity955 who need anticoagulation and antiplatelets.
